Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

Leuk Lymphoma. 2017 Sep;58(9):1-6. doi: 10.1080/10428194.2017.1283030. Epub 2017 Feb 9.

Authors

Affiliations

¹ a Department of Internal Medicine , The University of Texas Health Sciences Center at Houston , TX , USA.
² b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
³ c Chao Family Comprehensive Cancer Center, University of California , Irvine , CA , USA.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Blast Crisis
Female
Harringtonines / administration & dosage
Homoharringtonine
Humans
Imatinib Mesylate / administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myeloid, Chronic-Phase
Male
Middle Aged
Neoplasm Staging
Retreatment
Treatment Outcome
Young Adult

Substances

Harringtonines
Homoharringtonine
Imatinib Mesylate

Grants and funding